Cardiac Microinjury Measured by Troponin T Predicts Collagen Metabolism in Adults Aged ≥65 Years With Heart Failure

Background—Repeated myocardial microinjuries lead to collagen deposition and fibrosis, thereby increasing the risk of clinical heart failure. Little is known about the longitudinal association between increases in myocardial injury and the biology of collagen synthesis and deposition. Methods and Results—Repeated measures of highly sensitive cardiac troponin T (cTnT) were obtained in participants of the Cardiovascular Health Study (N=353; mean age, 74±6 years; 52% women) at baseline and at 3 years follow-up. Biomarkers of collagen metabolism were obtained at follow-up and included carboxyterminal propeptide of procollagen type I, carboxyterminal telopeptide of type I collagen, and aminoterminal propeptide of procollagen III. Multivariable linear regression analyses were used to examine the association between baseline cTnT and changes in cTnT with collagen metabolism markers at follow-up adjusting for demographics, heart failure status, and cardiovascular risk factors. Results indicated that cTnT increases over 3-years were significantly associated with higher levels of carboxyterminal telopeptide of type I collagen (&bgr;=0.22, P<0.001) and aminoterminal propeptide of procollagen III (&bgr;=0.12, P=0.035) at follow-up when adjusting for demographic, clinical, and biochemical covariates including baseline cTnT. These associations were stronger in patients with heart failure than in control subjects. Conclusions—Increases in myocardial microinjury measured by changes in cTnT adversely affect markers of collagen metabolism. These findings are important to the biology of myocardial fibrosis and tissue repair. Serial evaluation of cTnT combined with collagen metabolism markers may further elucidate the pathophysiology of heart failure.

[1]  A. Sharrett,et al.  Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study. , 2011, Clinical chemistry.

[2]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[3]  M. Zhan,et al.  Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. , 2010, JAMA.

[4]  Arantxa González,et al.  Circulating Biomarkers of Collagen Metabolism in Cardiac Diseases , 2010, Circulation.

[5]  Sungha Park,et al.  Delayed enhancement magnetic resonance imaging is a significant prognostic factor in patients with non-ischemic cardiomyopathy. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[6]  A. Jaffe,et al.  Analytical validation of a high-sensitivity cardiac troponin T assay. , 2010, Clinical chemistry.

[7]  J. Gottdiener,et al.  Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing. , 2010, Journal of the American College of Cardiology.

[8]  Emily A. Kuhl,et al.  Association between depressive symptoms and fibrosis markers: The Cardiovascular Health Study , 2010, Brain, Behavior, and Immunity.

[9]  U. Eriksson,et al.  Mechanisms of cardiac fibrosis in inflammatory heart disease. , 2009, Trends in cardiovascular medicine.

[10]  J. Gottdiener,et al.  Association Between Elevated Fibrosis Markers and Heart Failure in the Elderly: The Cardiovascular Health Study , 2009, Circulation. Heart failure.

[11]  Michael J. Pencina,et al.  Predicting the 30-Year Risk of Cardiovascular Disease: The Framingham Heart Study , 2009, Circulation.

[12]  B. Pitt,et al.  Extracellular Cardiac Matrix Biomarkers in Patients With Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure: Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Study , 2009, Circulation.

[13]  S. Donnelly,et al.  Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover , 2009, European journal of heart failure.

[14]  T. Arias,et al.  Biochemical markers of myocardial remodelling in hypertensive heart disease. , 2008, Cardiovascular research.

[15]  T. Kato,et al.  Mineralocorticoid Receptor Antagonism Ameliorates Left Ventricular Diastolic Dysfunction and Myocardial Fibrosis in Mildly Symptomatic Patients With Idiopathic Dilated Cardiomyopathy: A Pilot Study , 2005, Circulation.

[16]  P. Marino,et al.  Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. , 2004, Journal of cardiac failure.

[17]  Arantxa González,et al.  Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin: Relation to Myocardial Fibrosis , 2004, Circulation.

[18]  K. Weber,et al.  From inflammation to fibrosis: a stiff stretch of highway. , 2004, Hypertension.

[19]  M. Chiariello,et al.  Myocardial Collagen Turnover in Hypertrophic Cardiomyopathy , 2003, Circulation.

[20]  J. Dyck,et al.  Intracellular Action of Matrix Metalloproteinase-2 Accounts for Acute Myocardial Ischemia and Reperfusion Injury , 2002, Circulation.

[21]  B. Strauer,et al.  Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy , 2002, European journal of heart failure.

[22]  R. Tracy,et al.  Longitudinal Stability of Coagulation, Fibrinolysis, and Inflammation Factors in Stored Plasma Samples , 2001, Thrombosis and Haemostasis.

[23]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.

[24]  J. Gardin,et al.  Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. , 2000, Journal of the American College of Cardiology.

[25]  G. Mayor,et al.  Abnormalities of the extracellular degradation of collagen type I in essential hypertension. , 1998, Circulation.

[26]  Weber Kt.  Monitoring tissue repair and fibrosis from a distance. , 1997 .

[27]  L. Kuller,et al.  White blood cell counts in persons aged 65 years or more from the Cardiovascular Health Study. Correlations with baseline clinical and demographic characteristics. , 1996, American journal of epidemiology.

[28]  H. Eichler,et al.  Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. , 1995, The American journal of cardiology.

[29]  J. Díez,et al.  Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. , 1995, Circulation.

[30]  M. Cushman,et al.  Laboratory methods and quality assurance in the Cardiovascular Health Study. , 1995, Clinical chemistry.

[31]  K. Weber,et al.  Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.

[32]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[33]  J. Risteli,et al.  Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. , 1988, Clinical chemistry.

[34]  M. Caltagirone,et al.  PROCOLLAGEN TYPE I PRODUCTION BY HEPATOCYTES: A MARKER OF PROGRESSIVE LIVER DISEASE? , 1987, The Lancet.

[35]  Scott D Flamm,et al.  Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. , 2009, JACC. Cardiovascular imaging.

[36]  A. Wu,et al.  Short- and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay: implications for clinical practice. , 2009, Clinical chemistry.

[37]  P. Garnero,et al.  Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. , 2008, Clinical chemistry.

[38]  A. Zanchetti,et al.  Hypertensive myocardial fibrosis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[39]  R. R. Souza.  Aging of myocardial collagen , 2004, Biogerontology.

[40]  R. D. de Souza.  Aging of myocardial collagen , 2002, Biogerontology.

[41]  K. Weber.  Monitoring tissue repair and fibrosis from a distance. , 1997, Circulation.

[42]  R. Tracy,et al.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.